Illumina, Inc. $ILMN Position Boosted by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. lifted its stake in Illumina, Inc. (NASDAQ:ILMN) by 217.4% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 5,047 shares of the life sciences company’s stock after purchasing an additional 3,457 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Illumina were worth $662,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in the company. Capital World Investors boosted its position in shares of Illumina by 20.0% in the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock worth $1,897,178,000 after buying an additional 3,331,542 shares during the period. Nordea Investment Management AB boosted its position in shares of Illumina by 2,792.2% in the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock worth $124,145,000 after buying an additional 911,843 shares during the period. Massachusetts Financial Services Co. MA acquired a new position in shares of Illumina in the 4th quarter valued at about $73,532,000. State Street Corp increased its holdings in shares of Illumina by 6.8% in the 3rd quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock valued at $569,800,000 after purchasing an additional 382,520 shares during the period. Finally, Duquesne Family Office LLC acquired a new position in shares of Illumina in the 2nd quarter valued at about $28,682,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

NASDAQ:ILMN opened at $160.03 on Wednesday. Illumina, Inc. has a 1 year low of $85.00 and a 1 year high of $177.22. The firm’s fifty day simple moving average is $139.27 and its 200 day simple moving average is $134.20. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $24.21 billion, a PE ratio of 29.10, a PEG ratio of 2.96 and a beta of 1.50.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the prior year, the business earned $0.97 earnings per share. Illumina’s revenue for the quarter was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 5.2 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ILMN. Barclays upped their target price on Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a report on Friday, May 1st. Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. JPMorgan Chase & Co. lifted their target price on shares of Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a research note on Friday, May 1st. Canaccord Genuity Group decreased their target price on shares of Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a research note on Friday, May 1st. Finally, Evercore reaffirmed an “outperform” rating on shares of Illumina in a research report on Friday, May 1st. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $138.38.

Insider Transactions at Illumina

In other Illumina news, Director Keith A. Meister sold 235,000 shares of Illumina stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the sale, the director directly owned 2,830,452 shares of the company’s stock, valued at approximately $463,146,860.76. The trade was a 7.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Scott D. Ericksen sold 500 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total value of $80,000.00. Following the transaction, the chief accounting officer owned 14,446 shares of the company’s stock, valued at $2,311,360. This represents a 3.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,003,154 shares of company stock worth $155,600,208. 2.90% of the stock is currently owned by company insiders.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.